Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Vivelle Dot

×

Overview

What is Vivelle Dot?

Vivelle-Dot (estradiol transdermal system) contains estradiol in a multipolymeric adhesive. The system is designed to release estradiol continuously upon application to intact skin.

      Five dosage strengths of Vivelle-Dot are available to provide nominal delivery rates of 0.025, 0.0375, 0.05, 0.075, or 0.1 mg of estradiol per day via the skin. Each corresponding system has an active surface area of 2.5, 3.75, 5.0, 7.5, or 10.0 cm and contains 0.39, 0.585, 0.78, 1.17, or 1.56 mg of estradiol USP, respectively. The composition of the systems per unit area is identical.

      Estradiol USP is a white, crystalline powder, chemically described as estra-1,3,5 (10)-triene-3,17β-diol.

      The structural formula is

      The molecular formula of estradiol is CH0. The molecular weight is 272.39.

      Vivelle-Dot is comprised of three layers. Proceeding from the visible surface toward the surface attached to the skin, these layers are (1) a translucent polyolefin film (2) an adhesive formulation containing estradiol, acrylic adhesive, silicone adhesive, oleyl alcohol, NF, povidone, USP and dipropylene glycol, and (3) a polyester release liner which is attached to the adhesive surface and must be removed before the system can be used.

The active component of the system is estradiol. The remaining components of the system are pharmacologically inactive.



What does Vivelle Dot look like?



What are the available doses of Vivelle Dot?

Sorry No records found.

What should I talk to my health care provider before I take Vivelle Dot?

Sorry No records found

How should I use Vivelle Dot?

Vivelle-Dot (estradiol transdermal system) is indicated in:

      The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women.

The adhesive side of Vivelle-Dot (estradiol transdermal system) should be placed on a clean, dry area of the abdomen. Vivelle-Dot should be replaced twice weekly. The sites of application must be rotated, with an interval of at least 1 week allowed between applications to a particular site. The area selected should not be oily, damaged, or irritated. The waistline should be avoided, since tight clothing may rub the system off. The system should be applied immediately after opening the pouch and removing the protective liner. The system should be pressed firmly in place with the palm of the hand for about 10 seconds, making sure there is good contact, especially around the edges. In the event that a system should fall off, the same system may be reapplied. If the same system cannot be reapplied, a new system should be applied to another location. In either case, the original treatment schedule should be continued. If a woman has forgotten to apply a patch, she should apply a new patch as soon as possible. The new patch should be applied on the original treatment schedule. The interruption of treatment in women taking Vivelle-Dot might increase the likelihood of breakthrough bleeding, spotting and recurrence of symptoms.


What interacts with Vivelle Dot?

Sorry No Records found


What are the warnings of Vivelle Dot?

Sorry No Records found


What are the precautions of Vivelle Dot?

Sorry No Records found


What are the side effects of Vivelle Dot?

Sorry No records found


What should I look out for while using Vivelle Dot?

Vivelle-Dot (estradiol transdermal system) should not be used in women with any of the following conditions:

See

The use of unopposed estrogens in women who have a uterus is associated with an increased risk of endometrial cancer.


What might happen if I take too much Vivelle Dot?

Serious ill effects have not been reported following acute ingestion of large doses of estrogen-containing drug products by young children. Overdosage of estrogen may cause nausea and vomiting, and withdrawal bleeding may occur in females.


How should I store and handle Vivelle Dot?

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Keep tightly closed (protect from moisture). Protect from light.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Keep tightly closed (protect from moisture). Protect from light.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).Vivelle-Dot (estradiol transdermal system), 0.0375 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4920-0Vivelle-Dot (estradiol transdermal system), 0.05 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4242-0Vivelle-Dot (estradiol transdermal system), 0.075 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4243-0Vivelle-Dot (estradiol transdermal system), 0.1 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4244-0________________________________________*See DESCRIPTION.Store at controlled room temperature at 25ºC (77°F).Do not store unpouched. Apply immediately upon removal from the protective pouch.REV: AUGUST 2004                                                 T2004-65Vivelle-Dot (estradiol transdermal system), 0.0375 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4920-0Vivelle-Dot (estradiol transdermal system), 0.05 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4242-0Vivelle-Dot (estradiol transdermal system), 0.075 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4243-0Vivelle-Dot (estradiol transdermal system), 0.1 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4244-0________________________________________*See DESCRIPTION.Store at controlled room temperature at 25ºC (77°F).Do not store unpouched. Apply immediately upon removal from the protective pouch.REV: AUGUST 2004                                                 T2004-65Vivelle-Dot (estradiol transdermal system), 0.0375 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4920-0Vivelle-Dot (estradiol transdermal system), 0.05 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4242-0Vivelle-Dot (estradiol transdermal system), 0.075 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4243-0Vivelle-Dot (estradiol transdermal system), 0.1 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4244-0________________________________________*See DESCRIPTION.Store at controlled room temperature at 25ºC (77°F).Do not store unpouched. Apply immediately upon removal from the protective pouch.REV: AUGUST 2004                                                 T2004-65Vivelle-Dot (estradiol transdermal system), 0.0375 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4920-0Vivelle-Dot (estradiol transdermal system), 0.05 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4242-0Vivelle-Dot (estradiol transdermal system), 0.075 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4243-0Vivelle-Dot (estradiol transdermal system), 0.1 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4244-0________________________________________*See DESCRIPTION.Store at controlled room temperature at 25ºC (77°F).Do not store unpouched. Apply immediately upon removal from the protective pouch.REV: AUGUST 2004                                                 T2004-65Vivelle-Dot (estradiol transdermal system), 0.0375 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4920-0Vivelle-Dot (estradiol transdermal system), 0.05 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4242-0Vivelle-Dot (estradiol transdermal system), 0.075 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4243-0Vivelle-Dot (estradiol transdermal system), 0.1 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4244-0________________________________________*See DESCRIPTION.Store at controlled room temperature at 25ºC (77°F).Do not store unpouched. Apply immediately upon removal from the protective pouch.REV: AUGUST 2004                                                 T2004-65Vivelle-Dot (estradiol transdermal system), 0.0375 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4920-0Vivelle-Dot (estradiol transdermal system), 0.05 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4242-0Vivelle-Dot (estradiol transdermal system), 0.075 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4243-0Vivelle-Dot (estradiol transdermal system), 0.1 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4244-0________________________________________*See DESCRIPTION.Store at controlled room temperature at 25ºC (77°F).Do not store unpouched. Apply immediately upon removal from the protective pouch.REV: AUGUST 2004                                                 T2004-65Vivelle-Dot (estradiol transdermal system), 0.0375 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4920-0Vivelle-Dot (estradiol transdermal system), 0.05 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4242-0Vivelle-Dot (estradiol transdermal system), 0.075 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4243-0Vivelle-Dot (estradiol transdermal system), 0.1 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4244-0________________________________________*See DESCRIPTION.Store at controlled room temperature at 25ºC (77°F).Do not store unpouched. Apply immediately upon removal from the protective pouch.REV: AUGUST 2004                                                 T2004-65Vivelle-Dot (estradiol transdermal system), 0.0375 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4920-0Vivelle-Dot (estradiol transdermal system), 0.05 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4242-0Vivelle-Dot (estradiol transdermal system), 0.075 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4243-0Vivelle-Dot (estradiol transdermal system), 0.1 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4244-0________________________________________*See DESCRIPTION.Store at controlled room temperature at 25ºC (77°F).Do not store unpouched. Apply immediately upon removal from the protective pouch.REV: AUGUST 2004                                                 T2004-65Vivelle-Dot (estradiol transdermal system), 0.0375 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4920-0Vivelle-Dot (estradiol transdermal system), 0.05 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4242-0Vivelle-Dot (estradiol transdermal system), 0.075 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4243-0Vivelle-Dot (estradiol transdermal system), 0.1 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4244-0________________________________________*See DESCRIPTION.Store at controlled room temperature at 25ºC (77°F).Do not store unpouched. Apply immediately upon removal from the protective pouch.REV: AUGUST 2004                                                 T2004-65Vivelle-Dot (estradiol transdermal system), 0.0375 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4920-0Vivelle-Dot (estradiol transdermal system), 0.05 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4242-0Vivelle-Dot (estradiol transdermal system), 0.075 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4243-0Vivelle-Dot (estradiol transdermal system), 0.1 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4244-0________________________________________*See DESCRIPTION.Store at controlled room temperature at 25ºC (77°F).Do not store unpouched. Apply immediately upon removal from the protective pouch.REV: AUGUST 2004                                                 T2004-65Vivelle-Dot (estradiol transdermal system), 0.0375 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4920-0Vivelle-Dot (estradiol transdermal system), 0.05 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4242-0Vivelle-Dot (estradiol transdermal system), 0.075 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4243-0Vivelle-Dot (estradiol transdermal system), 0.1 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4244-0________________________________________*See DESCRIPTION.Store at controlled room temperature at 25ºC (77°F).Do not store unpouched. Apply immediately upon removal from the protective pouch.REV: AUGUST 2004                                                 T2004-65Vivelle-Dot (estradiol transdermal system), 0.0375 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4920-0Vivelle-Dot (estradiol transdermal system), 0.05 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4242-0Vivelle-Dot (estradiol transdermal system), 0.075 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4243-0Vivelle-Dot (estradiol transdermal system), 0.1 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4244-0________________________________________*See DESCRIPTION.Store at controlled room temperature at 25ºC (77°F).Do not store unpouched. Apply immediately upon removal from the protective pouch.REV: AUGUST 2004                                                 T2004-65Vivelle-Dot (estradiol transdermal system), 0.0375 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4920-0Vivelle-Dot (estradiol transdermal system), 0.05 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4242-0Vivelle-Dot (estradiol transdermal system), 0.075 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4243-0Vivelle-Dot (estradiol transdermal system), 0.1 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4244-0________________________________________*See DESCRIPTION.Store at controlled room temperature at 25ºC (77°F).Do not store unpouched. Apply immediately upon removal from the protective pouch.REV: AUGUST 2004                                                 T2004-65Vivelle-Dot (estradiol transdermal system), 0.0375 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4920-0Vivelle-Dot (estradiol transdermal system), 0.05 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4242-0Vivelle-Dot (estradiol transdermal system), 0.075 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4243-0Vivelle-Dot (estradiol transdermal system), 0.1 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4244-0________________________________________*See DESCRIPTION.Store at controlled room temperature at 25ºC (77°F).Do not store unpouched. Apply immediately upon removal from the protective pouch.REV: AUGUST 2004                                                 T2004-65Vivelle-Dot (estradiol transdermal system), 0.0375 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4920-0Vivelle-Dot (estradiol transdermal system), 0.05 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4242-0Vivelle-Dot (estradiol transdermal system), 0.075 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4243-0Vivelle-Dot (estradiol transdermal system), 0.1 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4244-0________________________________________*See DESCRIPTION.Store at controlled room temperature at 25ºC (77°F).Do not store unpouched. Apply immediately upon removal from the protective pouch.REV: AUGUST 2004                                                 T2004-65Vivelle-Dot (estradiol transdermal system), 0.0375 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4920-0Vivelle-Dot (estradiol transdermal system), 0.05 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4242-0Vivelle-Dot (estradiol transdermal system), 0.075 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4243-0Vivelle-Dot (estradiol transdermal system), 0.1 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4244-0________________________________________*See DESCRIPTION.Store at controlled room temperature at 25ºC (77°F).Do not store unpouched. Apply immediately upon removal from the protective pouch.REV: AUGUST 2004                                                 T2004-65Vivelle-Dot (estradiol transdermal system), 0.0375 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4920-0Vivelle-Dot (estradiol transdermal system), 0.05 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4242-0Vivelle-Dot (estradiol transdermal system), 0.075 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4243-0Vivelle-Dot (estradiol transdermal system), 0.1 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4244-0________________________________________*See DESCRIPTION.Store at controlled room temperature at 25ºC (77°F).Do not store unpouched. Apply immediately upon removal from the protective pouch.REV: AUGUST 2004                                                 T2004-65Vivelle-Dot (estradiol transdermal system), 0.0375 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4920-0Vivelle-Dot (estradiol transdermal system), 0.05 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4242-0Vivelle-Dot (estradiol transdermal system), 0.075 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4243-0Vivelle-Dot (estradiol transdermal system), 0.1 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4244-0________________________________________*See DESCRIPTION.Store at controlled room temperature at 25ºC (77°F).Do not store unpouched. Apply immediately upon removal from the protective pouch.REV: AUGUST 2004                                                 T2004-65Vivelle-Dot (estradiol transdermal system), 0.0375 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4920-0Vivelle-Dot (estradiol transdermal system), 0.05 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4242-0Vivelle-Dot (estradiol transdermal system), 0.075 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4243-0Vivelle-Dot (estradiol transdermal system), 0.1 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4244-0________________________________________*See DESCRIPTION.Store at controlled room temperature at 25ºC (77°F).Do not store unpouched. Apply immediately upon removal from the protective pouch.REV: AUGUST 2004                                                 T2004-65Vivelle-Dot (estradiol transdermal system), 0.0375 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4920-0Vivelle-Dot (estradiol transdermal system), 0.05 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4242-0Vivelle-Dot (estradiol transdermal system), 0.075 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4243-0Vivelle-Dot (estradiol transdermal system), 0.1 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4244-0________________________________________*See DESCRIPTION.Store at controlled room temperature at 25ºC (77°F).Do not store unpouched. Apply immediately upon removal from the protective pouch.REV: AUGUST 2004                                                 T2004-65Vivelle-Dot (estradiol transdermal system), 0.0375 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4920-0Vivelle-Dot (estradiol transdermal system), 0.05 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4242-0Vivelle-Dot (estradiol transdermal system), 0.075 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4243-0Vivelle-Dot (estradiol transdermal system), 0.1 mg/dayPatient Calendar Pack of 8 Systems……………………………………….NDC 54868-4244-0________________________________________*See DESCRIPTION.Store at controlled room temperature at 25ºC (77°F).Do not store unpouched. Apply immediately upon removal from the protective pouch.REV: AUGUST 2004                                                 T2004-65


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level.

      The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women.

      Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue.

      Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.

Non-Clinical Toxicology
Vivelle-Dot (estradiol transdermal system) should not be used in women with any of the following conditions:

See

The use of unopposed estrogens in women who have a uterus is associated with an increased risk of endometrial cancer.

Drug-drug interactions with Mefloquine Hydrochloride Tablets have not been explored in detail. There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a beta blocker (propranolol) (see ). The effects of mefloquine on the compromised cardiovascular system have not been evaluated. The benefits of mefloquine therapy should be weighed against the possibility of adverse effects in patients with cardiac disease.

1.

      Addition of a

p

rogestin

w

hen a

w

oman

h

as

n

ot

h

ad a

h

ysterectomy

.

2.

      Elevated

B

lood

P

ressure

.

3.

Hypertriglyceridemia.

4.

Impaired

L

iver

F

unction and

p

ast

h

istory of

c

holestatic

j

aundice.

5.

      Hypothyroidism.

6.

      Fluid

R

etention.

7.

      Hypocalcemia.

8.

      Ovarian

C

ancer.

9.

      Exacerbation of

E

ndometriosis.

10.

      Exacerbation of

O

ther

C

onditions.

See and

      Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.

      The following adverse events have been reported with Vivelle-Dot (estradiol transdermal system) therapy:

†

* NOS represents not otherwise specified

** NEC represents not elsewhere classified

*** Application site erythema and application site irritation were observed in a small number of patients (3.2% or less of patients across treatment groups.)

      The following additional adverse reactions have been reported with estrogen and/or progestin therapy:

1.

      Genitourinary system.

2.

      Breasts.

3.

      Cardiovascular.

4.

      Gastrointestinal.

5.

      Skin.

6.

      Eyes.

7.

      Central nervous system.

8.

      Miscellaneous.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).